The European Society of Endocrinology (ESE) and ENSAT 2018 guidelines recommend adjuvant mitotane treatment following resection of ACC in patients considered to have a high risk of recurrence (i.e., stage III, R1 resection, or Ki-67 > 10%) [32] as demonstrated in Figure 1. The gene discussed is MKI67; the disease is adrenal cortex carcinoma.